| Accelerated Amortized Payment of Bond Installment | 09-Jul-2026 | 07:00 | RNS |
| Avacta Appoints Patrick Vink Deputy Chairman | 08-Jul-2026 | 07:00 | RNS |
| FDA Agreement on Pivotal Trial Design for AVA6000 | 25-Jun-2026 | 07:00 | RNS |
| Platform-Validating Data with Faridoxorubicin | 25-Jun-2026 | 07:00 | RNS |
| Result of AGM | 23-Jun-2026 | 07:00 | RNS |
| Year-to-date business update ahead of AGM | 22-Jun-2026 | 07:00 | RNS |
| Oversubscribed Strategic Equity Fundraise of ... | 05-Jun-2026 | 07:00 | RNS |
| Block Listing - Application to AIM | 01-Jun-2026 | 15:00 | RNS |
| Clinical data on AVA6000 in salivary gland cancers | 01-Jun-2026 | 07:00 | RNS |
| Posting of Annual Report and Notice of AGM | 29-May-2026 | 07:00 | RNS |
| Board Director Changes | 29-May-2026 | 07:00 | RNS |
| Unaudited Preliminary Full Year 2025 Results | 19-May-2026 | 07:00 | RNS |
| Notice of Preliminary Results and Presentation | 13-May-2026 | 07:00 | RNS |
| Issue of Equity and Total Voting Rights | 13-May-2026 | 07:00 | RNS |
| Pre|CISION® payload release vs approved ADCs | 06-May-2026 | 07:00 | RNS |
| Currency | UK Pounds |
| Share Price | 66.00p |
| Change Today | 0.50p |
| % Change | 0.76 % |
| 52 Week High | 89.50 |
| 52 Week Low | 48.50 |
| Volume | 806,687 |
| Shares Issued | 471.33m |
| Market Cap | £311.08m |
| Beta | 0.01 |
| RiskGrade | 461 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| Time | Volume / Share Price |
| 16:27 | 15,186 @ 65.90p |
| 16:26 | 14,034 @ 65.90p |
| 16:26 | 3,894 @ 65.90p |
| 16:24 | 4,000 @ 66.69p |
| 16:15 | 12,904 @ 66.70p |
| CEO | Christina Coughlin |
| CFO | Brian Hahn |
You are here: research